The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 601–700 of 1,007
Suspected non-Alzheimer's pathology – Is it non-Alzheimer's or non-amyloid?
Dani, M., Brooks, D. J., & Edison, P. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.02.003 · Cited by 54
Cu II Binding to Various Forms of Amyloid‐β Peptides: Are They Friends or Foes?
Borghesani, V., Aliès, B., & Hureau, C. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201700776 · Cited by 59
New pyridine derivatives as inhibitors of acetylcholinesterase and amyloid aggregation
Pandolfi, F., Vita, D. D., Bortolami, M., Coluccia, A., Santo, R. D., Costi, R., Andrisano, V., Alabiso, F., Bergamini, C., Fato, R., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.022 · Cited by 50
Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus
Schirinzi, T., Sancesario, G. M., Lazzaro, G. D., D’Elia, A., Imbriani, P., Scalise, S., & Pisani, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1842-z · Cited by 53
“Approximately 10%, instead, is cleared into the CSF via the interstitial fluid (ISF) (Karran et al. 2011), passing through the “glymphatic system” (Iliff et al.”
BackgroundInfluentialvan Rooij, J. G. J., Meeter, L. H. H., Melhem, S., Nijholt, D. A. T., Wong, T. H., Rozemuller, A., Uitterlinden, A. G., van Meurs, J. G., & van Swieten, J. C. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.023 · Cited by 49
“Previous studies have shown neurodegenerative changes in the hippocampus 15e20 years before symptom onset (Boyle et al., 2013; Karran et al., 2011; Murray et al., 2011).”
Key Peptides and Proteins in Alzheimer’s Disease
Penke, B., Bogár, F., Paragi, G., Gera, J., & Fülöp, L. (2019) · Current Protein & Peptide Science · doi:10.2174/1389203720666190103123434 · Cited by 49
Early Cognitive and Behavioral Deficits in Mouse Models for Tauopathy and Alzheimer’s Disease
Samaey, C., Schreurs, A., Stroobants, S., & Balschun, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00335 · Cited by 60
Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition
Burnham, S. C., Laws, S. M., Budgeon, C. A., Doré, V., Porter, T., Bourgeat, P., Buckley, R. F., Murray, K., Ellis, K. A., Turlach, B. A., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.001 · Cited by 57
Kerbage, C., Sadowsky, C., Tariot, P. N., Agronin, M., Alva, G., Turner, F. D., Nilan, D., Cameron, A., Cagle, G. D., & Hartung, P. D. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513520214 · Cited by 54
Derakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48
Bignante, E. A., Heredia, F., Morfini, G. A., & Lorenzo, A. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.021 · Cited by 60
“The most accepted mechanistic hypothesis for AD posits that abnormal aggregation and accumulation of Ab in the brain trigger a cascade of pathologic events leading to progressive neuronal dysfunction (Hardy, 2009; Hardy and Selkoe, 2002; Huang and Mucke, 2012; Karran et al., 2011).”
Icariin Prevents Amyloid Beta-Induced Apoptosis via the PI3K/Akt Pathway in PC-12 Cells
Zhang, D., Wang, Z., Sheng, C., Peng, W., Hui, S., Gong, W., & Chen, S. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/235265 · Cited by 53
“According to the amyloid hypothesis, neurodegeneration and dementia in AD are caused by extensive accumulation of amyloid beta peptide (Aβ) in the cerebrum [4, 5].”
An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome
Belichenko, P. V., Madani, R., Rey-Bellet, L., Pihlgren, M., Becker, A., Plassard, A., Vuillermot, S., Giriens, V., Nosheny, R. L., Kleschevnikov, A. M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152471 · Cited by 48
“The ability to reverse behavioral changes supports a model of pathogenesis in which toxic species are envisioned to serve as ‘drivers’ of changes in neuronal structure and function [51].”
BackgroundWnt/TLR Dialog in Neuroinflammation, Relevance in Alzheimer’s Disease
Zolezzi, J. M., & Inestrosa, N. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00187 · Cited by 47
Zhang, L., Trushin, S., Christensen, T. A., Tripathi, U., Hong, C. C., Geroux, R. E., Howell, K. G., Poduslo, J. F., & Trushina, E. V. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.003 · Cited by 59
Traditional Oriental Medicines and Alzheimer’s Disease
Jeon, S. G., Song, E. J., Lee, D., Park, J., Nam, Y., Kim, J.-I., & Moon, M. (2018) · Aging and Disease · doi:10.14336/ad.2018.0328 · Cited by 50
“Key words: Alzheimer’s disease, Oriental herbal medicine, Herbal formulae, Dementia Alzheimer’s disease (AD), the most major cause of dementia, is a progressive neurodegenerative disease involving characteristic pathologic changes, including the accumulation of β-amyloid (Aβ) and neurofibrillary tangles (NFT) [1-4].”
BackgroundShanmuganathan, B., Sathya, S., Balasubramaniam, B., Balamurugan, K., & Devi, K. P. (2019) · Nitric Oxide · doi:10.1016/j.niox.2019.07.009 · Cited by 48
Tsai, C., Liang, C., Lee, J., Su, M., Lin, C., Chu, H., Tsai, C., Lin, G., Lin, Y., & Yang, F. (2019) · Journal of Clinical Medicine · doi:10.2139/ssrn.3464407 · Cited by 54
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 47
Overview of therapeutic targets in management of dementia
Malik, R., Kalra, S., Bhatia, S., Al‐Harrasi, A., Singh, G., Mohan, S., Makeen, H. A., Albratty, M., Meraya, A. M., Bahar, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113168 · Cited by 55
“Consequently, more doubt raises about this Aβ concept [42].”
BackgroundMechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
Mohlenhoff, B. S., O’Donovan, A., Weiner, M. W., & Neylan, T. C. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0835-1 · Cited by 47
Liu, Y.-H., Bu, X.-L., Liang, C.-R., Wang, Y.-R., Zhang, T., Jiao, S.-S., Zeng, F., Yao, X.-Q., Zhou, H.-D., Deng, J., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0379-4 · Cited by 47
“Senile plaque containing amyloid-beta (Aβ) protein are a major hallmark of Alzheimer’s disease (AD) and have been considered as an important therapeutic target of AD [1, 2].”
BackgroundFranks, K. H., Chuah, M. I., King, A. E., & Vickers, J. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00234 · Cited by 55
“According to the amyloid cascade hypothesis of AD pathogenesis (Hardy and Higgins, 1992), Aβ deposition in the brain triggers a series of events that ultimately leads to the development of the disease (Karran et al., 2011).”
Bhakta, H. K., Park, C. H., Yokozawa, T., Tanaka, T., Jung, H. A., & Choi, J. S. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0924-z · Cited by 48
“Therefore, targeting Ab accumulation is also a major focus in the development of novel AD therapies (Selkoe 2001; Hardy and Selkoe 2002; Karran et al. 2011; Mucke and Selkoe 2012).”
BackgroundJan, A. T., Azam, M., Rahman, S., Almigeiti, A. M. S., Choi, D. H., Lee, E. J., Haq, Q. M. R., & Choi, I. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00356 · Cited by 47
“Over the time, substantial evidences regarding accumulation of misfolded Aβ and tau tangles (so-called seeds of pathological consequences) in the brain of patients suffering from AD have been established (Karran et al., 2011).”
BackgroundCoelho, D. S., Schwartz, S., Merino, M. M., Hauert, B., Topfel, B., Tièche, C. C., Rhiner, C., & Moreno, E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.098 · Cited by 49
Sun, H., Leng, H., Liu, J., Roy, G., Yan, J., & Zhang, L. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.127509 · Cited by 47
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 53
Association of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline
Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson, N., Hansson, O., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000013228 · Cited by 57
“Currently, the most widely accepted explanation for AD pathogenesis is the amyloid cascade hypothesis, which proposes that AD is initiated primarily by accumulation of the β-amyloid (Aβ) peptide into senile plaques, sequentially followed by the accumulation of misfolded tau protein into tangles, neuronal loss, and cog…”
BackgroundGut microbiome and Alzheimer’s disease: What we know and what remains to be explored
Kapoor, B., Biswas, P., Gulati, M., Rani, P., & Gupta, R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102570 · Cited by 46
Platt, T. L., Reeves, V. L., & Murphy, M. P. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.017 · Cited by 46
An effective treatment for Alzheimer's disease must consider both amyloid and tau
Lansdall, C. J. (2014) · Bioscience Horizons · doi:10.1093/biohorizons/hzu002 · Cited by 46
Optimization of a Natural Product-Based Class of γ-Secretase Modulators
Hubbs, J. L., Fuller, N. O., Austin, W., Shen, R., Creaser, S. P., McKee, T. D., Loureiro, R. M. B., Tate, B. A., Xia, W., Ives, J. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300976b · Cited by 48
Deora, G. S., Kantham, S., Chan, S., Dighe, S. N., Veliyath, S. K., McColl, G., Parat, M., McGeary, R. P., & Ross, B. P. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00229 · Cited by 48
Beneficial effects of white wine polyphenols-enriched diet on Alzheimer’s disease-like pathology
Mendes, D., Oliveira, M. M., Moreira, P. I., Coutinho, J., Nunes, F. M., Pereira, D. M., Valentão, P., Andrade, P. B., & Videira, R. A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.02.001 · Cited by 55
Yang, K., Zeng, C. C., Wang, C., Sun, M., Yin, D., & Sun, T. (2020) · Molecules · doi:10.3390/molecules25225439 · Cited by 50
“Aβ is produced via a two-step cleavage of the amyloid precursor peptide (APP) by β secretase and γ secretase (also called presenilin (PS)) [105].”
BackgroundDumas, M., & Davidovic, L. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9578-5 · Cited by 54
Metal binding ability of curcumin derivatives: a theoretical vs. experimental approach
Ferrari, É., Asti, M., Benassi, R., Pignedoli, F., & Saladini, M. (2013) · Dalton Transactions · doi:10.1039/c3dt33072a · Cited by 46
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls
Mattsson, N., Insel, P. S., Donohue, M., Jagust, W., Sperling, R., Aisen, P., & Weiner, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4530 · Cited by 45
Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders
Balana, A. T., & Pratt, M. R. (2021) · Biochemical Journal · doi:10.1042/bcj20200609 · Cited by 47
Ependymal cells and neurodegenerative disease: outcomes of compromised ependymal barrier function
Nelles, D. G., & Hazrati, L. (2022) · Brain Communications · doi:10.1093/braincomms/fcac288 · Cited by 41
“One hypothesis of Alzheimer’s disease pathogenesis is the amyloid cascade hypothesis, which states that the accumulation and deposition of amyloid plaques initiates neurodegeneration and drives the downstream formation of neurofibrillary tangles.(77) Since ependymal cells are essential for the removal of metabolic was…”
BackgroundMicrotechnologies for single-cell and spatial multi-omics
Deng, Y., Bai, Z., & Fan, R. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00084-y · Cited by 46
Cu(II) enhances the effect of Alzheimer’s amyloid-β peptide on microglial activation
Yu, F., Gong, P., Hu, Z., Qiu, Y., Cui, Y., Gao, X., Chen, H., & Li, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0343-3 · Cited by 44
“Amyloid-β (Aβ) peptides are key molecules in AD pathology as they aggregate to form amyloid plaques, the primary neuropathological hallmarks of AD [3].”
BackgroundAβ42-Binding Peptoids as Amyloid Aggregation Inhibitors and Detection Ligands
Luo, Y., Vali, S., Sun, S., Chen, X., Liang, X., Drozhzhina, T., Александровна, П. Е., & Борисович, Б. И. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400011f · Cited by 50
Bales, K. R. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.666234 · Cited by 45
“Significant progress in understanding the pathophysiological mechanisms associated with sporadic AD has been derived from studying autosomal dominant familial forms of AD that result from the inheritance of mutations found in three genes: amyloid precursor protein (APP), Presenilin-1 (PS1) and Presenilin-2 (PS2) [19,2…”
BackgroundRational heterodoxy: Cholesterol reformation of the amyloid doctrine
Castello, M. A., & Soriano, S. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.007 · Cited by 45
Stimulate or Degenerate: Deep Brain Stimulation of the Nucleus Basalis Meynert in Alzheimer Dementia
Hardenacke, K., Kuhn, J., Lenartz, D., Maarouf, M., Mai, J. K., Bartsch, C., Freund, H. J., & Sturm, V. (2012) · World Neurosurgery · doi:10.1016/j.wneu.2012.12.005 · Cited by 51
Korabecny, J., Andrs, M., Nepovimova, E., Dolezal, R., Babkova, K., Horova, A., Malinak, D., Mezeiova, E., Gorecki, L., Sepsova, V., et al. (2015) · Molecules · doi:10.3390/molecules201219836 · Cited by 45
“Among them, extracellular deposits of β-amyloid (Aβ), hyper-phosphorylated neurofibrillary tangles (NFT) of tau protein, reactive oxygen species (ROS), metal imbalance and disrupted cholinergic system have received particular attention [3–7].”
BackgroundSomavarapu, A. K., & Kepp, K. P. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.02.008 · Cited by 45
Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer’s disease
Kang, S. S., Ahn, E. H., & Ye, K. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00494-7 · Cited by 48
“Consequently, the Tau (1-368) fragment is more robust than Tau FL (fulllength) in binding to active STAT1, a BACE1 transcription factor, and promotes its nuclear translocation, upregulating BACE1 and Aβ production.”
BackgroundMethodInfluentialCho, H.-J., Huynh, T. T., Rogers, B. E., & Mirica, L. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014058117 · Cited by 57
“The major neuropathological hallmark of AD is the deposition of extracellular amyloid plaques consisting of the beta-amyloid (Aβ) peptide (1, 2), and more recently the smaller, soluble Aβ oligomers have been shown to be involved in the synapse loss and neuronal injury occurring prior to the onset of AD (3–6).”
Kerbage, C., Sadowsky, C., Jennings, D. L., Cagle, G. D., & Hartung, P. D. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00062 · Cited by 53
“According to the amyloid cascade hypothesis, the accumulation of β-amyloid (Aβ) deposits as amyloid plaques in the patient’s brain is the primary event in the pathogenesis of AD (Hardy and Selkoe, 2002; Jack et al., 2010; Karran et al., 2011; Reiman et al., 2012).”
BackgroundTang, S., Ji, M., Chen, L., Hu, M. Y., Long, Y., Li, Y., Miao, M., Li, J.-C., Li, N., Ji, H., et al. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001314 · Cited by 46
“central disease-causing and disease-promoting event in the process of AD (Hardy and Allsop, 1991; Karran et al., 2011).”
BackgroundChang, C., Liu, Y., Lin, H., Hsu, C., Cheng, B., Liu, W., Lin, M., Hsu, S.-F., Chang, L., & Lin, K. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9623-2 · Cited by 46
Audrain, M., Fol, R., Dutar, P., Potier, B., Billard, J.-M., Flament, J., Alves, S., Burlot, M.-A., Dufayet-Chaffaud, G., Bemelmans, A.-P., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0070-y · Cited by 43
“Our results support the importance of the Aβ42/ Aβ40 ratio to trigger initial neuronal dysfunctions in vivo.”
BackgroundInfluentialSchoenfeld, H. A., West, T., Verghese, P. B., Holubasch, M. S., Shenoy, N., Kagan, D., Buono, C., Zhou, W., DeCristofaro, M. F., Douville, J., et al. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.03.014 · Cited by 48
“The amyloid cascade hypothesis posits that abnormal production and clearance of Aβ contributes to the formation of amyloid plaques, commonly found in the brains of patients with dementia due to Alzheimer's disease (AD) (Karran et al., 2011).”
BackgroundTherapeutic Targeting of Casein Kinase 1δ/ε in an Alzheimer’s Disease Mouse Model
Adler, P., Mayne, J., Walker, K., Ning, Z., & Figeys, D. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00312 · Cited by 46
Hein, Z. M., Karikalan, B., Gopalakrishna, P. K., Dhevi, K., Alkatiri, A., Hussan, F., Mohd Moklas, M. A., Jagadeesan, S., Che Ramli, M. D., Che Mohd Nassir, C. M. N., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05602-0 · Cited by 43
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
Borgegård, T., Gustavsson, S., Nilsson, C., Parpal, S., Klintenberg, R., Berg, A.-L., Rosqvist, S., Serneels, L., Svensson, S., Olsson, F., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1451-12.2012 · Cited by 43
“In AD the Amyloid peptide (A ), which is generated from the processing of amyloid precursor protein (APP) by the enzyme -secretase, aggregates to form neural plaques, which induces a cascade of events resulting in neuronal loss and dementia (Karran et al., 2011).”
Self-citationGPR3 Stimulates Aβ Production via Interactions with APP and β-Arrestin2
Nelson, C. D., & Sheng, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074680 · Cited by 45
Peroxisome Proliferator-activated Receptors and Alzheimer's Disease: Hitting the Blood–Brain Barrier
Zolezzi, J. M., & Inestrosa, N. C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8435-5 · Cited by 49
“Indeed, from these observations, it has been proposed that enhancing the cellular antioxidant mechanism could prevent neurodegeneration [50, 86, 117, 118].”
BackgroundMandal, M., Wu, Y., Misiaszek, J., Li, G., Buevich, A. V., Caldwell, J. P., Liu, X., Mazzola, R., Orth, P., Strickland, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01995 · Cited by 45
Inhibition of β-Amyloid Aggregation through a Designed β-Hairpin Peptide
Jha, A., Kumar, M. G., Gopi, H. N., & Paknikar, K. M. (2017) · Langmuir · doi:10.1021/acs.langmuir.7b03617 · Cited by 43
Malaiya, M. K., Jain, A., Hurkat, P., Jain, A., & Jain, D. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.03.030 · Cited by 45
Inhibiting Aβ toxicity in Alzheimer's disease by a pyridine amine derivative
Zhu, Z., Yang, T., Zhang, L., Liu, L., Yin, E., Zhang, C., Guo, Z., Chen, X., & Wang, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.052 · Cited by 48
Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases
Murakami, K., Izuo, N., & Bitan, G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101478 · Cited by 45
DAPK1: a Novel Pathology and Treatment Target for Alzheimer’s Disease
Xu, L.-Z., Li, B.-Q., & Jia, J.-P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1242-2 · Cited by 42
Secretases Related to Amyloid Precursor Protein Processing
Liu, X., Liu, Y., & Ji, S. (2021) · Membranes · doi:10.3390/membranes11120983 · Cited by 47
Resveratrol as a Therapeutic Agent in Alzheimer’s Disease: Evidence from Clinical Studies
Puranik, N., Kumari, M., Tiwari, S., Dhakal, T., & Song, M. (2025) · Nutrients · doi:10.3390/nu17152557 · Cited by 55
“The failure to clear A β efficiently is considered to play a pivotal role in the onset and progression of the disease [3].”
Ramaker, J. M., Swanson, T. L., & Copenhaver, P. F. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1146-13.2013 · Cited by 55
“However, therapeutic strategies targeting A have been unsuccessful (Karran et al., 2011), suggesting that other APP-related processes may contribute to the disease (Mangialasche et al., 2010).”
BackgroundTransthyretin-Derived Peptides as β-Amyloid Inhibitors
Cho, P. Y., Joshi, G., Johnson, J. A., & Murphy, R. M. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500014u · Cited by 42
Postsynaptic Proteome of Non-Demented Individuals with Alzheimer’s Disease Neuropathology
Zolochevska, O., Bjorklund, N., Woltjer, R., Wiktorowicz, J. E., & Taglialatela, G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180179 · Cited by 42
Arrigoni, F., Prosdocimi, T., Mollica, L., GIOIA, L. D., Zampella, G., & Bertini, L. (2018) · Metallomics · doi:10.1039/c8mt00216a · Cited by 43
Jha, A., Ghormade, V., Kolge, H., & Paknikar, K. M. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00162j · Cited by 42
Timmers, M., Tesseur, I., Bogert, J., Zetterberg, H., Blennow, K., Börjesson-Hanson, A., Baquero, M., Boada, M., Randolph, C., Tritsmans, L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.016 · Cited by 42
Fujimoto, K., Matsuoka, E., Asada, N., Tadano, G., Yamamoto, T., Nakahara, K., Fuchino, K., Ito, H., Kanegawa, N., Moechars, D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00309 · Cited by 47
Stress and the Etiopathogenesis of Alzheimer’s Disease and Depression
Sotiropoulos, I., Silva, J. M., Gomes, P., Sousa, N., & Almeida, O. F. X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_20 · Cited by 44
Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders
Hanif, S., Muhammad, P., Niu, Z., Ismail, M., Morsch, M., Zhang, X., Li, M., & Shi, B. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100008 · Cited by 47
Liu, W., Zhang, H., Dong, X., & Sun, Y. P. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.03.019 · Cited by 42
Spires-Jones, T. L., Friedman, T., Pitstick, R., Polydoro, M., Roe, A., Carlson, G. A., & Hyman, B. T. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.01.013 · Cited by 41
Dineen, T. A., Weiss, M. M., Williamson, T., Acton, P., Babu-Khan, S., Bartberger, M. D., Brown, J., Chen, K., Cheng, Y., Citron, M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300118s · Cited by 41
Liu, H., Dong, X., Liu, F., Zheng, J., & Sun, Y. P. (2017) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2017.06.093 · Cited by 43
Ye, B. S., Kim, H. J., Kim, Y. J., Jung, N., Lee, J. S., Lee, J., Jang, Y. K., Yang, J., Lee, J. M., Vogel, J. W., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23676-w · Cited by 46
“We hypothesized that (1) PiB(+) aMCI patients have greater risk of progression to dementia compared to PiB(−) aMCI patients; and (2) there could be certain features predicting progression to dementia in PiB(−) aMCI patients.”
BackgroundDual-functional red-emitting fluorescent probes for imaging beta-amyloid plaques and viscosity
Tan, H.-Y., Zhou, K., Yan, J., Sun, H., Pistolozzi, M., Cui, M., & Zhang, L. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.126903 · Cited by 43
Temperature and toxic Tau in Alzheimer's disease: new insights
Carrettiero, D. C., Santiago, F. E., Motzko-Soares, A. C. P., & Almeida, M. C. (2015) · Temperature · doi:10.1080/23328940.2015.1096438 · Cited by 44
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease
Maggiore, A., Casale, A. M., Toscanelli, W., Cappucci, U., Rotili, D., Grieco, M., Gagné, J.-P., Poirier, G. G., d’Erme, M., & Piacentini, L. (2022) · Cells · doi:10.3390/cells11081284 · Cited by 40
“Therefore, Aβ42 is pred cted to be the most potentially efficient target of drug therapies [80].”
BackgroundChoriocapillaris reduction accurately discriminates against early‐onset Alzheimer's disease
Kwapong, W. R., Tang, F., Liu, P., Zhang, Z., Cao, L., Feng, Z., Yang, S., Shu, Y., Xu, H., Lu, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13871 · Cited by 40
“26 Presently, the diagnosis of preclinical AD relies on A β positron emission tomography (PET), cerebrospinal fluid (CSF), or blood A β or tau levels.”
Alzheimer's disease research and development: a call for a new research roadmap
Feldman, H. H., Haas, M., Gandy, S., Schoepp, D. D., Cross, A. J., Mayeux, R., Sperling, R. A., Fillit, H., van de Hoef, D. L., Dougal, S., et al. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12424 · Cited by 40
Hall, D. R., Kardos, J., Edskes, H. K., Carver, J. A., & Goto, Y. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.01.032 · Cited by 41
Fleisher, A., Joshi, A. D., Sundell, K. L., Chen, Y., Kollack‐Walker, S., Lu, M., Chen, S., Devous, M. D., Seibyl, J. P., MAREK, K. L., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.009 · Cited by 41
“Although a number of randomized clinical trials have focused on drug therapies targeting reduced production or increased clearance of Ab within the brain as a potential treatment for AD [6,7], the outcomes of these studies have not consistently demonstrated a benefit in slowing cognitive or functional decline nor in r…”
BackgroundChen, Y., Lin, H., Zhu, J., Gu, K., Li, Q., He, S., Lü, X., Tan, R. X., Pei, Y., Wu, L., et al. (2017) · RSC Advances · doi:10.1039/c7ra04385f · Cited by 41
The Role of Apolipoprotein E Isoforms in Alzheimer’s Disease
Roda, A. R., Montoliu-Gaya, L., & Villegas, S. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180740 · Cited by 39
“Although the exact pathological mechanism of AD is still under discussion, according to the amyloid hypothesis, abnormal aggregation of A (cid:2) in the brain would be the early event that triggers the pathogenic cascade leading to the disease development [3].”
Physical activity and beta-amyloid pathology in Alzheimer's disease: A sound mind in a sound body
Ebrahimi, K., Majdi, A., Baghaiee, B., Hosseini, S. H., & Sadigh‐Eteghad, S. (2017) · EXCLI journal · doi:10.17179/excli2017-475 · Cited by 46
“Hence, in most familial AD cases, Aβ42/Aβ40 ratio is elevated in the brain which predisposes individuals to AD (Karran et al., 2011; Kumar‐Singh et al., 2006).”
BackgroundInfluentialChen, J., Long, Z., Li, Y., Luo, M., Luo, S., & He, G. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4198 · Cited by 56
Hu, Y., Yang, J. W., Zhang, Y. L., Liu, K., Liu, T., Sun, J., & Wang, X. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1615484 · Cited by 40
A facile biosensor for Aβ40O based on fluorescence quenching of prussian blue nanoparticles
Chen, W., Gao, G., Jin, Y., & Deng, C. (2020) · Talanta · doi:10.1016/j.talanta.2020.120930 · Cited by 44
Voits, T., Pliatsikas, C., Robson, H., & Rothman, J. (2020) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2020.107593 · Cited by 49
“According to the Amyloid Cascade Hypothesis (Karran et al., 2011), the dominant theory in AD research, in this type of dementia the brain is subject to aggregation of Aβ protein, and formation of cortical amyloid plaques.”
Tokgöz, S., & Claassen, J. A. H. R. (2021) · Cardiology and Therapy · doi:10.1007/s40119-020-00209-z · Cited by 42
“We searched the literature in the PubMed electronic database using the following search terms: physical activity, exercise, aerobic fitness, training, sport, APOE4, Alzheimer’s disease, AD and dementia.”
BackgroundInfluential
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.